Showing 211 - 220 of 258 for "Hugill & Ip" with applied filters
19 September 2017 by
This week's moves came at Hicksons, Johnson Winter & Slattery, Corrs Chambers Westgarth, Thomson Geer and DibbsBarker in Australia, while IndusLaw added two partners to its Hyderabad team.
04 September 2017 by
The Intellectual Property Office of New Zealand (IPONZ) became a participant patent office in the Global Patent Prosecution Highway (GPPH) on July 6.
01 September 2017 by
New Balance has won in a trade mark infringement dispute in a first instance decision from the Suzhou Intermediate People’s Court. The court ordered the defendants to pay damages and legal costs of RMB10 million ($1.47 million) in a case involving the use of the shoemaker’s slanting logo.
25 August 2017 by
India has a new set of guidelines for examinations of computer related inventions that are more favourable to patentees by removing a novel hardware requirement that was stipulated in the previous guidelines. However, Indian IP practitioners see ambiguities that may lead to unsuitable patents being granted.
21 August 2017 by
Practitioners have welcomed Intellectual Property Office of Singapore (IPOS) amendments to the patent regime to spur innovation and improve the quality of patents granted there.
18 August 2017 by
President Trump has authorised an inquiry into China’s alleged theft of the intellectual property of US companies. While some believe this to be Trump’s way of forcing China to increase pressure against North Korea to stop developing nuclear weapons, others think Trump’s concern about how IP theft is affecting US businesses is genuine.
08 August 2017 by
Latest moves and updates from Hong Kong, India and Singapore
02 August 2017 by
From the Taj Mahal Palace Hotel to the Nokia ringtone and the stripes of 7-Eleven convenience stores, Karry Lai explains why non-traditional trade mark innovation in Asia is more than meets the eye
27 July 2017 by
The China Food and Drug Administration (CFDA) is planning to introduce a patent linkage scheme that will require a generic applicant to make a non-infringement declaration against an innovator’s patent portfolio. By creating this linkage, innovators can rest assured that their innovations are protected while generic drug companies are motivated to get regulatory approval for entry into market by proving that a patent is invalid or not infringed. However, observers warn of potential challenges in implementation.
26 June 2017 by
Latest partner moves and firm updates from Singapore, Australia and India